Related Experiment Video
Updated: Jan 12, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.7K
Botulinum toxin for chronic migraine.
Lejla Paracka1, Dirk Dressler2,3
1Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. paracka.lejla@mh-hannover.de.
Journal of Neural Transmission (Vienna, Austria : 1996)
|November 6, 2025
Summary
Botulinum toxin (BoNT) offers a promising treatment for chronic migraine (CM), especially when standard therapies fail. Clinical trials confirm BoNT
Area of Science:
- Neurology
- Pain Management
- Pharmacology
Background:
- Chronic migraine (CM) is a debilitating condition affecting 15+ days/month.
- Standard treatments often prove challenging or cause adverse effects.
- Botulinum toxin (BoNT) is an emerging therapeutic option for CM.
Purpose of the Study:
- To review the efficacy and safety of Botulinum toxin (BoNT) for chronic migraine (CM).
Main Methods:
- Review of multiple randomized controlled trials (RCTs) on BoNT for CM.
- Analysis of BoNT's mechanism in modulating pain pathways.
- Assessment of clinical outcomes regarding headache frequency and safety.
Main Results:
- BoNT demonstrated significant reductions in headache frequency in CM patients.
- Clinical efficacy and safety of BoNT for CM are supported by RCTs.
- BoNT is particularly beneficial for patients unresponsive to standard treatments.
Conclusions:
- Botulinum toxin (BoNT) is an effective and safe treatment for chronic migraine (CM).
- BoNT offers a valuable therapeutic strategy for refractory CM cases.
- Further understanding of BoNT's role in pain modulation is supported.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
869
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
869
01:20Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
01:26Cholinergic Antagonists: Therapeutic Uses
1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.4K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
869
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
869